Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias, An international multi-center study

  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, G.
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Houtkamp, I.M.
  • Koel-Simmerlink, M.
  • Verberk, I.M.W.
  • Gaetani, L.
  • Toja, A.
  • Wojdała, A.L.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.
  • van der Flier, W.
  • Hort, J.
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • González-Escalante, Armand
  • Contador, José
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Ortiz-Romero, Paula|||0000-0002-6378-6763
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Minguillón, Carolina
  • Campo Milán, Marta del|||0000-0003-2808-3699
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Otto, M.|||0000-0003-4273-4267
INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. RESULTS: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. DISCUSSION: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.